Vimarsana
Biggest News Aggregation in the World

Page 10 - Vida Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Vida Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Vida Ventures Today - Breaking & Trending Today

Affini-T Therapeutics, Inc.: Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations - Vimarsana News

Affini-T Therapeutics, Inc.: Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

Co-founded at Fred Hutchinson Cancer Research Center with Phil Greenberg, M.D., Aude Chapuis, M.D., and Tom Schmitt, Ph.D., and Vida Ventures along with serial entrepreneurs Arjun Goyal, M.D., M.Phil.

Cell therapy biotech Affini-T gets $175M; KRAS is lead genomic cancer target - Vimarsana News

Cell therapy biotech Affini-T gets $175M; KRAS is lead genomic cancer target

Affini-T Therapeutics is developing new cell therapies for cancer that could overcome limitations of the first generation of cell therapies. The initial genomic cancer targets of the startup are mutations of KRAS and p53, both of which have proven difficult to drug.

A2 Bio publishes key preclinical findings demonstrating potential of its highly selective Tmod™ cell therapy platform to revolutionize the treatment of solid tumors in select patients - Vimarsana News

A2 Bio publishes key preclinical findings demonstrating potential of its highly selective Tmod™ cell therapy platform to revolutionize the treatment of solid tumors in select patients

/PRNewswire/ -- A2 Biotherapeutics, Inc. ("A2 Bio''), a biotechnology company focused on the treatment of solid tumors, announced today that key preclinical...

A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod™ Cell - Vimarsana News

A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod™ Cell

AGOURA HILLS, Calif.--(BUSINESS WIRE)--#A2Bio--A2 Biotherapeutics, Inc. (“A2 Bio''), a biotechnology company focused on the treatment of solid tumors, announced today that key preclinical data related to its proprietary Tmod™ cell therapy platform have been published in Science Translational Medicine and Journal for...

A2 Bio publishes key preclinical findings demonstrating potential of its highly selective Tmod™ cell therapy platform to revolutionize the treatment of solid tumors in select patients - Vimarsana News

A2 Bio publishes key preclinical findings demonstrating potential of its highly selective Tmod™ cell therapy platform to revolutionize the treatment of solid tumors in select patients

/PRNewswire/ -- A2 Biotherapeutics, Inc. ("A2 Bio''), a biotechnology company focused on the treatment of solid tumors, announced today that key preclinical...